PUNE, India, November 15, 2016 /PRNewswire/ --
ReportsnReports.com adds "Bladder Cancer - Pipeline Review, H2 2016"to its store, providing comprehensive information on the therapeutics under development for Bladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report
Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.
Complete report on Global Bladder Cancer Market Research with 151 market data tables and 17 figures, spread across 742 pages is available at http://www.reportsnreports.com/reports/747719-bladder-cancer-pipeline-review-h2-2016.html .
Company Analysis and Positioning discussed in this research are 4SC AG, Adaptimmune Therapeutics Plc, ADC Therapeutics SA, Agenus Inc, Altor BioScience Corporation, AndroScience Corporation, APIM Therapeutics AS, Arno Therapeutics, Inc., Astellas Pharma Inc., Astex Pharmaceuticals Inc, Aura Biosciences, Inc., AVEO Pharmaceuticals, Inc., Azaya Therapeutics, Inc., Bavarian Nordic A/S, Bayer AG
BioCancell Ltd, Biomics Biotechnologies Co., Ltd., Bioncotech Therapeutics SL, Biotest AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Cellceutix Corporation, Celldex Therapeutics, Inc., Celprogen, Inc., Celsion Corporation, Codagenix, Inc., Cold Genesys, Inc., Corvus Pharmaceuticals Inc, CytomX Therapeutics, Inc., DormaTarg, Inc., Eisai Co., Ltd., Eleven Biotherapeutics Inc., Eli Lilly and Company, Elsalys Biotech SAS, enGene, Inc, Esperance Pharmaceuticals, Inc., Exelixis, Inc., F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., Gene Signal International SA, Genmab A/S, GlaxoSmithKline Plc, H3 Biomedicine Inc., Hamlet Pharma AB, Heat Biologics, Inc., HEC Pharm Co., Ltd., Hutchison MediPharma Limited, Idera Pharmaceuticals, Inc., ImmuNext, Inc., Immunocore Limited, Immunomedics, Inc., Immupharma Plc, InteRNA Technologies B.V., Johnson & Johnson, LipoMedix Pharmaceutical Inc., MacroGenics, Inc., MaxiVAX SA, Meabco A/S, Medicenna Therapeutics, Inc., MedImmune LLC, Merck & Co., Inc., Merck KGaA, Mirati Therapeutics Inc., Mirna Therapeutics, Inc., Miyarisan Pharmaceutical Company, Ltd, Moleculin Biotech Inc, NanoCarrier Co., Ltd., Nektar Therapeutics, NuCana BioMed Limited, Omeros Corporation, Oncogenex Pharmaceuticals, Inc., Oncolytics Biotech Inc., OncoTherapy Science, Inc., Ono Pharmaceutical Co., Ltd., Optimum Therapeutics, LLC, Pfizer Inc., Pharma Mar, S.A., Philogen S.p.A., Plexxikon Inc., Polaris Pharmaceuticals, Inc., Provectus Biopharmaceuticals, Inc., PsiOxus Therapeutics Limited, Rexahn Pharmaceuticals, Inc., Rodos BioTarget GmbH, Sanofi, Savoy Pharmaceuticals, Inc., Serometrix, LLC, Shionogi & Co., Ltd., Sillajen Biotherapeutics, Sorrento Therapeutics Inc, Spectrum Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Sun Pharma Advanced Research Co Ltd, Synovo GmbH, Taiwan Liposome Company, Ltd., Tara Immuno-Oncology Therapeutics LLC, Taris Biomedical LLC, Telormedix SA, TesoRx Pharma LLC, Theravectys SA, Theryte Limited, Transgene SA, UroGen Pharmaceuticals, Ltd., Vakzine Projekt Management GmbH, Vault Pharma Inc., Vaxeal Holding SA, Vaxiion Therapeutics, Inc. and Viralytics Ltd.
Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=747719 .
The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 44, 35, 2, 56 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 2 molecules, respectively.
Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Explore more reports on Pharmaceuticals.
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact: Ritesh Tiwari 2nd floor, metropole, Next to inox theatre, Bund garden road, Pune-411001 Maharashtra, India. Tel: +1-888-391-5441 [email protected]
Connect With Us on:
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
Subscribe to our Free Newsletters!
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...
Proton beam therapy is a type of external radiation treatment or radiotherapy that uses protons ...
Statins are a group of drugs which help to lower the blood cholesterol levels.View All